According to
a new research report “Herpes
simplex virus infections Therapeutic Pipeline Analysis, - Clinical
Trials & Results, Patent, Designation, Collaboration, and Other
Developments” published by P&S Intelligence, Herpes simplex virus
infections Therapeutic pipeline currently exhibits a pipeline with 20 drug
candidates.
The study
analysed that the Herpes simplex virus infections pipeline comprises of 20 drug
candidates in different stages of development.
Insights on
pipeline segments
As per the
findings of the research, most of the drug candidates are being developed to be
administered by oral route.
New
innovating technologies offer development of promising drugs
Request
to Get the Sample Pages at:
Many
technologies are being developed that offer promising innovative treatments
which can control the progression of Herpes simplex virus infections. The
technologies include, but not limited to, Vector based technology platform,
AdenoVerse technology platform, Juvari’s technology platform and Nanostat
technology platform.
Major
companies collaborate for the development of Herpes simplex virus infections
Pipeline
The research
found that various companies have collaborated for the development of Herpes simplex
virus infections pipeline. In June 2014, PaxVax Inc., entered into a research
and development collaboration with the University of California to develop a
combination vaccine to prevent genital herpes simplex virus infections.
Some of the
key players developing drugs for the treatment of Herpes virus simplex
infections include Maruho Co., Ltd., NanoBio Corporation, Lumavita AG and
others.
Herpes
Simplex Virus Infections Therapeutics Pipeline Analysis
By Phase
By Route of
Administration
By Molecule Type
By Company
